The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The Cancer Clinical Decision Tools Market During The Forecast Period?
The cancer clinical decision tools market has experienced robust expansion over recent years. Projections indicate it will increase from $0.55 billion in 2025 to $0.6 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 9.0%. This historical growth is largely due to factors such as increasing cancer incidence rates, the escalating workload on primary care physicians, a scarcity of early diagnostic tools in primary care, a heightened focus on the precision of referrals, and the expansion of hospital and clinic infrastructure.
The cancer clinical decision tools market is projected to undergo significant expansion in the coming years. This market is expected to reach $0.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.2%. The anticipated growth within this forecast period stems from the advancement of AI-driven decision tools, the integration of genomic and risk profiling data, the expansion of digital health platforms, a rise in government screening initiatives, and the increasing adoption of evidence-based oncology guidelines. Major developments observed during this period encompass the growing acceptance of clinical decision support tools in oncology, a heightened focus on early cancer detection and risk stratification, the expanding use of symptom checkers and risk calculators by GPs, the broadening of guideline-based referral and decision frameworks, and the integration of cancer decision tools into primary care workflows.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3463&type=smp
Which Strong Drivers Are Impacting The Cancer Clinical Decision Tools Market Growth?
The increase in cancer prevalence is anticipated to fuel the expansion of the cancer clinical decision tools market moving forward. Cancer incidence denotes the number of new cancer cases diagnosed within a specific demographic during a particular timeframe, indicating the disease’s frequency. This rise in incidence is linked to increased exposure to risk factors such as unhealthy lifestyles, which can eventually result in genetic mutations and abnormal cell growth. Cancer clinical decision tools assist in tracking, predicting, and managing cancer cases more efficiently, enabling early detection and timely intervention that can influence observed cancer incidence trends. For instance, according to the NHS England, a UK-based publicly funded healthcare system, there were 354,820 new cancer diagnoses in 2023 by October 2025, marking an increase of 8,605 from 2022. Therefore, the worldwide growth in cancer incidence rates will heighten the demand for the cancer clinical decision tools market.
What Are The Different Segment Types In The Cancer Clinical Decision Tools Market Segment Breakdown?
The cancer clinical decision tools market covered in this report is segmented –
1) By Type: Risk Assessment Tool(RAT), Qcancer
2) By End-User: Hospital, Clinics
Subsegments:
1) By Risk Assessment Tool (RAT): Family History Assessment, Genetic Testing and Counseling, Lifestyle and Environmental Risk Factors Evaluation
2) By Qcancer: Symptom Checker, Risk Calculator, Guideline-Based Recommendations
Which Trends Are Influencing Demand In The Cancer Clinical Decision Tools Market?
Leading firms within the cancer clinical decision tools market are progressively adopting AI-driven prognostic decision support systems. This adoption addresses the expanding requirement for individualized, data-centric oncology care, fueled by increasing cancer rates, the necessity for improved risk stratification, and the imperative to streamline treatment protocols. Such AI prognostic systems employ deep-learning models to examine various data types, including imaging, electronic health records, and clinical biomarkers. This analysis allows for predictions of outcomes such as survival, risk of recurrence, or treatment efficacy with considerably greater accuracy compared to conventional rule-based instruments. As an illustration, in February 2025, Onc.AI, a US-based health-tech enterprise, announced that its Serial CTRS (Cancer Treatment Risk Stratification) tool received FDA Breakthrough Device Designation. This AI-powered tool categorizes non–small cell lung cancer (NSCLC) patients into high- and low-risk mortality categories by processing diagnostic imaging scans using a deep-learning algorithm, consequently aiding oncologists in making more educated choices regarding treatment intensity and subsequent care. The capacity of Serial CTRS to forecast long-term survival outcomes facilitates superior patient stratification, more customized treatment strategies, and improved resource deployment. This marks a significant progression beyond traditional prognostic models, which often depend on a restricted set of clinical indicators.
Who Are The Well-Known Companies In The Cancer Clinical Decision Tools Market?
Major companies operating in the cancer clinical decision tools market are McKesson Corporation, Philips Healthcare, Siemens Healthineers AG, Elsevier B.V., National Decision Support Company, Cerner Corporation, GE Healthcare, Allscripts Healthcare Solutions Inc., Epic Systems Corporation, RaySearch Laboratories AB, Elekta AB, Varian Medical Systems Inc., Accuray Incorporated, F. Hoffmann-La Roche Ltd., Flatiron Health Inc., Tempus Labs Inc., NantHealth Inc., Syapse Inc., Inspirata Inc., Prognos Health Inc., Deep 6 AI Inc., PathAI Inc.
Get The Full Cancer Clinical Decision Tools Market Report:
https://www.thebusinessresearchcompany.com/report/cancer-clinical-decision-tool-global-market-report
Where Is The Cancer Clinical Decision Tools Market Primarily Concentrated By Region?
North America was the largest region in the cancer clinical decision tools market in 2025. The regions covered in the cancer clinical decision tools market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cancer Clinical Decision Tools Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/cancer-clinical-decision-tool-global-market-report
Browse Through More Reports Similar to the Global Cancer Clinical Decision Tools Market 2026, By The Business Research Company
Polymerase Chain Reactions Devices Reagents And Uses Market Report 2026
Cardiovascular Monitoring And Diagnostic Devices And Equipment Market Report 2026
Veterinary Diagnostic Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model